Association of endothelial lipase Thr111Ile polymorphism with lipid metabolism and microvascular complications in type 2 diabetic patients;Association du polymorphisme Thr111Ile de la lipase endothéliale avec les paramètres lipidiques du sérum et les complications microvasculaires chez des patients diabétiques de type 2

Diabetes and Metabolism

Volumn 37, Issue 1, 2011, Pages 64-71

  Durlach, V ^a,c   Durlach, A ^b   Movesayan, I ^c   Socquard, E ^a   Zellner, C ^c   Clavel, C ^b   Nazeyrollas, P ^a   Malloy, M J ^c   Pullinger, C R ^c   Kane, J P ^c   Ducasse, A ^a   Aouizerat, B E ^c  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetic retinopathy; Endothelial lipase; Genetics; HDL cholesterol; Polymorphism of endothelial lipase gene; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; ENDOTHELIAL LIPASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BODY MASS; DIABETIC RETINOPATHY; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GENOTYPE; HOMOZYGOSITY; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; RETINOPATHY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; LIPASE; LIPID METABOLISM; LONGITUDINAL STUDIES; MALE; MICROCIRCULATION; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79951769131     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.07.010     Document Type: Article

References (48)

1. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987, 3:463-524.
2. Dunn F.L. Hyperlipidemia in diabetes mellitus. Diabetes Metab Rev 1990, 6:47-61.
3. Vergès B. Lipid modification in type 2 diabetes: the role of LDL and HDL. Fundam Clin Pharmacol 2009, 23:681-685.
4. Jaye M., Lynch K.J., Krawiec J., Marchadier D., Maugeais C., Doan K., et al. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999, 21:424-428.
5. Rader D.J., Jaye M. Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol 2000, 11:141-147.
6. Hirata K., Dichek H.L., Cioffi J.A., Choi S.Y., Leeper N.J., Quintana L., et al. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem 1999, 274:14170-14175.
7. Cohen J.C. Endothelial lipase: direct evidence for a role in HDL metabolism. J Clin Invest 2003, 111:318-321.
8. Zhang Q., Cavallero E., Hoffmann M.M., Cavanna J., Kay A., Charles A., et al. Mutations at the lipoprotein lipase gene locus in subjects with diabetes mellitus, obesity and lipaemia. Clin Sci (Lond) 1997, 93:335-341.
9. Lamarche B., Paradis M.E. Endothelial lipase and the metabolic syndrome. Curr Opin Lipidol 2007, 18:298-303.
10. Jaye M., Krawiec J. Endothelial lipase and HDL metabolism. Curr Opin Lipidol 2004, 15:183-189.
11. Ma K., Cilingiroglu M., Otvos J.D., Ballantyne C.M., Marian A.J., Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc Natl Acad Sci U S A 2003, 100:2748-2753.
12. Yamakawa-Kobayashi K., Yanagi H., Endo K., Arinami T., Hamaguchi H. Relationship between serum HDL-C levels and common genetic variants of the endothelial lipase gene in Japanese school-aged children. Hum Genet 2003, 113:311-315.
13. deLemos A.S., Wolfe M.L., Long C.J., Sivapackianathan R., Rader D.J. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 2002, 106:1321-1326.
14. Hutter C.M., Austin M.A., Farin F.M., Viernes H.M., Edwards K.L., Leonetti D.L., et al. Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans. Atherosclerosis 2006, 185:78-86.
15. West M.S., Herd J.A., Ballantyne C.M., Pownall H.J., Simpson S., Gould L., et al. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials 1996, 17:550-583.
16. Shimizu M., Kanazawa K., Hirata K., Ishida T., Hiraoka E., Matsuda Y., et al. Endothelial lipase gene polymorphism is associated with acute myocardial infarction, independently of high-density lipoprotein-cholesterol levels. Circ J 2007, 71:842-846.
17. Fujii H., Fukuda A., Tanaka M., Kojima Y., Ishida T., Hirata K., et al. Putative role of endothelial lipase in dialysis patients with hypoalbuminemia and inflammation. Am J Nephrol 2008, 28:974-981.
18. DeSantis P., Coleman T., Schiekofer S., Nawroth P.P., Schlimmer P., Schneider J.G., et al. Endothelial Lipase: a key player in HDL metabolism modulates inflammation and atherosclerotic risk. Mini Rev Med Chem 2008, 8:619-627.
19. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
20. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97:1029-1036.
21. West K.M., Ahuja M.M., Bennett P.H., Czyzyk A., De Acosta O.M., Fuller J.H., et al. The role of circulating glucose and triglyceride concentrations and their interactions with other " risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983, 6:361-369.
22. Solini A., Passaro A., Fioretto P., Nannipieri M., Ferrannini E. Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes. J Intern Med 2004, 256:30-36.
23. Mattu R.K., Trevelyan J., Needham E.W., Khan M., Adiseshiah M.A., Richter D. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetes. Diabetologia 2002, 45:905-913.
24. Murata M., Maruyama T., Suzuki Y., Saruta T., Ikeda Y. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med 2004, 21:837-844.
25. Cheung N., Mitchell P., Wong T.Y. Diabetic retinopathy. Lancet 2010, 376:124-136.
26. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979, 28:1039-1057. National Diabetes Data Group.
27. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991, 98(Suppl. 5):786-806. Early Treatment Diabetic Retinopathy Study Research Group.
28. Chen X., Levine L., Kwok P.Y. Fluorescence polarization in homogeneous nucleic acid analysis. Genome Res 1999, 9:492-498.
29. Kwok P.Y. SNP genotyping with fluorescence polarization detection. Hum Mutat 2002, 19:315-323.
30. Ko B.C., Lam K.S., Wat N.M., Chung S.S. An (A-C)n dinucleotide repeat polymorphic marker at the 5' end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995, 44:727-732.
31. Abhary S., Burdon K.P., Laurie K.J., Thorpe S., Landers J., Goold L., et al. Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility. Diabetes Care 2010, 33:1834-1836.
32. Warpeha K.M., Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye (Lond) 2003, 17:305-311.
33. Awata T., Kurihara S., Takata N., Neda T., Iizuka H., Ohkubo T., et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun 2005, 333:679-685.
34. Abhary S., Hewitt A.W., Burdon K.P., Craig J.E. A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 2009, 58:2137-2147.
35. Fong D.S., Aiello L., Gardner T.W., King G.L., Blankenship G., Cavallerano J.D., et al. Diabetic retinopathy. Diabetes Care 2003, 26:226-229.
36. Taverna M.J. Genetics of diabetic complications: retinopathy. Ann Endocrinol (Paris) 2004, 65(Suppl. 1):S17-S25.
37. Warpeha K.M., Chakravarthy U. Molecular genetics of microvascular disease in diabetic retinopathy. Eye 2003, 17:305-311.
38. Shimokawa Y., Hirata K., Ishida T., Kojima Y., Inoue N., Quertermous T., et al. Increased expression of endothelial lipase in rat models of hypertension. Cardiovasc Res 2005, 66:594-600.
39. Badellino K.O., Wolfe M.L., Reilly M.P., Rader D.J. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 2006, 3:e22.
40. Mohamed Q., Gillies M.C., Wong T.Y. Management of diabetic retinopathy: a systematic review. JAMA 2007, 298:902-916.
41. Ishida B.Y., Bailey K.R., Duncan K.G., Chalkley R.J., Burlingame A.L., Kane J.P., et al. Regulated expression of apolipoprotein E by human retinal pigment epithelial cells. J Lipid Res 2004, 45:263-271.
42. shida B.Y., Duncan K.G., Bailey K.R., Kane J.P., Schwartz D.M. High density lipoprotein mediated lipid efflux from retinal pigment epithelial cells in culture. Br J Ophthalmol 2006, 90:616-620.
43. Im E., Motiejunaite R., Aranda J., Park E.Y., Federico L., Kim T.I., et al. Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression. Mol Cell Biol 2010, 30:2401-2410.
44. Qiu G., Hill J.S. Endothelial lipase promotes apolipoprotein AI-mediated cholesterol efflux in THP-1 macrophages. Arterioscler Thromb Vasc Biol 2009, 29:84-91.
45. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet 2005, 366:1829-1831.
46. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
47. Keech A.C., Mitchell P., Summanen P.A., O'Day J., Davis T.M., Moffitt M.S., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
48. The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 Diabetes. N Engl J Med 2010;363:233-44.